31![STEP THERAPY POLICY Nasal Steroids Preferred Step Therapy Program To Initiate a Coverage Review, Call[removed]DRUGS AFFECTED: Beconase AQ® (beclomethasone nasal spray – GlaxoSmithKline) STEP THERAPY POLICY Nasal Steroids Preferred Step Therapy Program To Initiate a Coverage Review, Call[removed]DRUGS AFFECTED: Beconase AQ® (beclomethasone nasal spray – GlaxoSmithKline)](https://www.pdfsearch.io/img/ccf87bb7ec0b9f7bc8595f8b33e4ffec.jpg) | Add to Reading ListSource URL: statehealthplan.state.nc.usLanguage: English - Date: 2014-09-02 09:27:20
|
---|
32![DOCUMENT INFORMATION PAGE DOCUMENT INFORMATION PAGE](https://www.pdfsearch.io/img/84d3d4b22d2f35af7ddcb9e64327df44.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 2004-09-14 08:01:38
|
---|
33![](https://www.pdfsearch.io/img/4af3d02c8dd7ddfd353785f6cf2deeb0.jpg) | Add to Reading ListSource URL: www.aaia.caLanguage: English - Date: 2010-06-22 02:56:55
|
---|
34![These highlights do not include all the information needed to use XYZAL safely and effectively. See full prescribing information for XYZAL. XYZAL (levocetirizine dihydrochloride) 5 mg tablets 2.5 mg/5 mL (0.5 mg/mL) oral These highlights do not include all the information needed to use XYZAL safely and effectively. See full prescribing information for XYZAL. XYZAL (levocetirizine dihydrochloride) 5 mg tablets 2.5 mg/5 mL (0.5 mg/mL) oral](https://www.pdfsearch.io/img/4e7ae3520c63b08b5dbc66c80e0af476.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
35![Abbreviated Process for PAC- No Presentation Full Safety Review Provided in Briefing Packet * Patanase Spray (olopatadine HCl) * Astepro Spray (azelastine HCl) * Bepreve (bepotastine besilate ophthalmic solution) 1.5% * Abbreviated Process for PAC- No Presentation Full Safety Review Provided in Briefing Packet * Patanase Spray (olopatadine HCl) * Astepro Spray (azelastine HCl) * Bepreve (bepotastine besilate ophthalmic solution) 1.5% *](https://www.pdfsearch.io/img/80906afff56f8536cc6d28850e438e3b.jpg) | Add to Reading ListSource URL: www.fda.gov |
---|
36![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ASTEPRO® Nasal Spray safely and effectively. See full prescribing information for ASTEPRO Nasal Spray. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ASTEPRO® Nasal Spray safely and effectively. See full prescribing information for ASTEPRO Nasal Spray.](https://www.pdfsearch.io/img/6dd79fd36e8c6f990aba872334a78284.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-09-21 16:08:17
|
---|
37![CLINICAL REVIEW Application Type Submission Number Submission Code CLINICAL REVIEW Application Type Submission Number Submission Code](https://www.pdfsearch.io/img/311ede52e4205c36a83acaa0bdfc71f6.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
38![[removed]Azelastine Clinical1 PREA [removed]Azelastine Clinical1 PREA](https://www.pdfsearch.io/img/d82a229c782a121a5e1b38aca8a86a84.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
39![022288_Bepotastine_Clinical_PREA 022288_Bepotastine_Clinical_PREA](https://www.pdfsearch.io/img/13f1f2290f06fe88a6ad00e8f53aa43d.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
40![[removed]Azelastine Statistical1 PREA [removed]Azelastine Statistical1 PREA](https://www.pdfsearch.io/img/ed57db15c8b6897a7afaf9e90f2a9b77.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|